# AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

> **NCT06767527** · PHASE3 · RECRUITING · sponsor: **Akeso** · enrollment: 416 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer (TNBC)

## Interventions

- **DRUG:** AK112
- **DRUG:** Nab-paclitaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06767527
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-07
- **Primary completion:** 2026-12
- **Final completion:** 2028-12
- **Target enrollment:** 416 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06767527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06767527, "AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT06767527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*